Navigation Links
Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
Date:4/15/2008

- New Approach to Targeting the Tumor Microenvironment -

SAN DIEGO, April 15 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced new pre-clinical findings on the treatment of prostate cancer models at the American Association for Cancer Research (AACR) conference. Halozyme is investigating its Pegylated-rHuPH20 enzyme (PEGrHuPH20) as a candidate for the systemic treatment of tumors rich in hyaluronan (HA) in combination with chemotherapy.

The studies explored the physiologic responses to enzymatic removal of HA-based matrices surrounding tumor cells in the tumor microenvironment of prostate tumors following systemic administration of its PEGrHuPH20 pre-clinical candidate. In animal pharmacokinetic models, PEGrHuPH20 demonstrated a more than 2,000-fold increase in plasma half-life compared to the unmodified enzyme. Prostate tumors were grown around the bone as a model of elevated interstitial fluid pressure (IFP). Treatment commenced when tumors had reached approximately 500 mm3 in size and pressure within the tumor had reached 30-40 mm Hg.

The objectives of these studies were to determine whether HA-dependent pericellular matrices produced in vitro and in vivo by hormone refractory prostate cancer cell line could be enzymatically depleted in prostate carcinoma xenografts following intravenous (IV) administration of the PEGrHuPH20 enzyme. The dose dependent effects of systemic enzyme treatment were evaluated by a combination of direct micropressure measurements, magnetic resonance imaging (MRI), ultrasound, immunohistochemistry, and determination of tumor water content. A summa
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
2. Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer
3. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
4. Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System
5. Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
6. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
7. CV Therapeutics Anti-Ischemic Therapy Ranexa(R) Significantly Reduces Cardiac Chest Pain Symptoms and Recurrent Ischemia in MERLIN-TIMI 36 Patients With Angina
8. Michael J. Fox Foundation Commits up to $10 Million for Pre-Clinical Drug Development Under Therapeutics Development Initiative
9. Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions
10. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
11. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015  ViewRay™, a privately held medical device company, announced ... agreement with ITOCHU Corporation (Tokyo Stock Exchange TYO: 8001) ... treatment of cancer in Japan . ... first and only MRI-guided radiation therapy system that images ...
(Date:1/22/2015)... /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), ... for cardiovascular disease and overall health is pleased to provide ... and its outlook for 2015 from the CEO, Mr. ... We would like to take this opportunity to share with ...
(Date:1/22/2015)... 2015 Increasing sophistication among enterprise buyers of language ... in 2015, says Moravia CMO, Renato ... by market research firm Common Sense Advisory, 15 percent ... translation and localization needs. "From a language industry perspective, ...
Breaking Medicine Technology:ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7Moravia Sees Single-Sourcing as Key Localization Trend in 2015 2
(Date:1/22/2015)... 20 years, Dr. David Cruz of Cruz Chiropractic Care ... about every type of injury that can result from car accidents ... years, the team at Doctors on Liens has been ... With the combined breadth of experience between the two, ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Yesterday, ... Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were honored ... leadership in advancing biotechnology, biomedical science, medical device ... Olsen each received the “2014 Life Sciences Champion” ...
(Date:1/22/2015)... WASHINGTON, DC (PRWEB) January 22, 2015 ... conditions in vulnerable communities and cause financial distress to ... report by analysts at Howard University’s Center on Race ... of dollars in economic activity, payday loans at the ...
(Date:1/22/2015)... January 22, 2015 Compare-autoinsurance.org has released a new ... by an auto insurance policy . , Some types ... Clients should check the newly released blog post to see if ... and dangerously damaged vehicles are some of the cars that cannot ...
(Date:12/26/2014)... (PRWEB) December 26, 2014 The US represents ... this report. In 2013, GlobalData’s forecast estimates that sales of ... CRC market due to the high incidence of the disease, ... the 5EU, Japan, and China. Increased sales of CRC therapies ...
Breaking Medicine News(10 mins):Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 3Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 4
... , ROYAL PALM BEACH, Fla. , Feb. 4 ... (one in three) suffer from some type of cardiovascular disease. Many ... an exciting sports event like the Super Bowl or World Cup ... comparison of death rates from heart attacks in 2002 and 2001, ...
... with natural tissue , THURSDAY, Feb. 4 (HealthDay News) ... in joints has been developed by U.S. researchers. , ... stimulates bone marrow stem cells to produce natural cartilage, ... therapy can do this, according to the researchers, from ...
... , , NORFOLK, Va. , Feb. 4 ... care for the victims of the devastating earthquake in Haiti ... sent three highly skilled medical teams and over 2 1/2 tons ... two days.  The Operation Smile volunteer teams, which are comprised of ...
... N.J. , Feb 4 Smart Balance, Inc. (Nasdaq: ... on February 25, 2010 , at 9:30 a.m. ET ... 8:30 a.m. ET the same day.  The webcast will be ... call by dialing 1-800-895-0198 from the United States or 1-785-424-1053 ...
... ... how it drives social change , ... Morgantown, WV (PRWEB) February 4, 2010 -- Virtual Global, a leading ... SaaS applications, has launched its new portal for cloud computing information, Cloudipedia. The site, ...
... , SACRAMENTO, Calif. , Feb. 4 ... Romans , CEO and Meg Heim, RN , Vice President ... P.A.D. Task Force Committee on behalf of the Governor of ... and the California Department of Chronic Disease and Injury Prevention (CDPH). ...
Cached Medicine News:Health News:Top 10 Ways to Avoid a Heart Attack This Super Bowl 2Health News:Top 10 Ways to Avoid a Heart Attack This Super Bowl 3Health News:Nanofiber Gel May Spur Growth of New Knee Cartilage 2Health News:Operation Smile Expands Its Medical Efforts to Help Earthquake Victims in Haiti 2Health News:Operation Smile Expands Its Medical Efforts to Help Earthquake Victims in Haiti 3Health News:Operation Smile Expands Its Medical Efforts to Help Earthquake Victims in Haiti 4Health News:Operation Smile Expands Its Medical Efforts to Help Earthquake Victims in Haiti 5Health News:Smart Balance to Host Webcast/Conference Call on 2009 Fourth-Quarter Results 2Health News:Virtual Global Launches Cloudipedia.com to Help Cloud Computing Newbies 2Health News:Virtual Global Launches Cloudipedia.com to Help Cloud Computing Newbies 3Health News:BioMedix Vascular Solutions, Inc. Invited to Participate in the California P.A.D. Task Force Committee 2
New - Color Coded Berman Airways. A simple idea makes size identification easier for you., ,Premium upgrade without a premium price. Color Coded Berman airways are latex-free., ,Plastic. Single use...
... Fome-Cuf® Oral/Nasal Wire Reinforced Endotracheal ... kit is packaged individually and includes ... Maintenance Device (CMD™), and 15 mm ... provides maximum patient safety by helping ...
... Portex® Blue Line® uncuffed ... Magill or Murphy styles, in ... ,Blue Line® adult and pediatric ... from implant-tested polyvinyl chloride with ...
... Ruschelit® PVC. 2 eyes, oral. Marked ... age. X-ray opaque line. Graduated. Single ... Designed to reduce kinking of the ... Thermosensitive Ruschelit® PVC adapts to the ...
Medicine Products: